Clinical and Translational Oncology

, Volume 14, Issue 9, pp 682–688

Immunohistochemical expression of cyclooxygenase-2 in patients with advanced cancer of the larynx who have undergone induction chemotherapy with the intention of preserving phonation

  • Elisabeth Pérez-Ruiz
  • O. Cazorla
  • M. Redondo
  • L. Pérez
  • M. Álvarez
  • E. Gallego
  • J. M. Trigo
  • J. A. Medina
  • A. Matilla
  • A. Rueda
Research Article



Cyclooxygenase-2 (COX2) is an enzyme that plays a role in different stages of the carcinogenic process and has prognostic and predictive values that have not yet been established. The objective of this study was to evaluate the role of COX2 overexpression in advanced squamous cell carcinoma of the larynx that has been treated with a phonation conservation protocol.

Materials and methods

This study included a retrospective analysis of 59 patients with resectable tumours that were treated with chemotherapy (CT) and/or radiation therapy (RT). The expression levels of COX2, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and vascular endothelial growth factor receptor (VEGFR-2) in collected biopsy specimens were determined via immunohistochemistry.


Forty-four percent of the included samples demonstrated overexpression of COX2. In the statistical analysis, COX2 overexpression did not correlate with other clinical or treatment efficacy prognostic factors; however, the median global survival (OS) of patients whose tumours expressed COX2 was 79 months, whereas COX2-negative patients had a median OS of only 38 months, although this finding did not reach statistical significance. The other analysed biological parameters did not demonstrate a significant relationship with COX2.


COX2 overexpression was a common finding in our study. The results obtained did not reveal relationships with established prognostic categories; however, the difference in survival between patients with and without COX2 expression justifies the need for future prospective studies that utilise a larger patient sample size.


Cyclooxygenase-2 Squamous cell carcinoma of the larynx Phonation conservation 


  1. 1.
    Rodrigo Tapia JP (2002) Incidencia y etiología de los carcinomas de cabeza y cuello. In: Suárez Nieto C (ed) Oncología de cabeza y cuello. Medicina stm, Barcelona, pp 1–14Google Scholar
  2. 2.
    The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiotherapy compared with surgery plus radiotherapy in patients with advances laryngeal cancer. N Engl J Med 324:1685–1690CrossRefGoogle Scholar
  3. 3.
    Schantz SP, Harrison LB, Forastiere AA (1997) Tumors of the nasal cavity and paranasal sinuses, nasophatrinx, oral cavity and oropharynx. In: De vita VT, Hellman S, Rosenberg SA (eds) Principles of oncology, 5th edn. Lippincott, Philadephia, pp 741–801Google Scholar
  4. 4.
    Liu CH, Chang SH, Narko K et al (2001) Over-expression of cyclooxigenasa (Cox)-2 is sufficient to induce tumorigenesis in transgenic. Biol Chem 276:18563–18569CrossRefGoogle Scholar
  5. 5.
    Masferrer JL, Leía KM, Kaki AT et al (2000) Antiogenic and antitumor activities of cyclooxygenase 2 inhibitors. Cancer Res 60:1306–1311PubMedGoogle Scholar
  6. 6.
    Ristimaki A, Sivula A, Lunfin J et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62:632–635PubMedGoogle Scholar
  7. 7.
    Shim JY et al (2003) Overexpression of cyclooxigenase-2 is associated with breast carcinoma and its poor prognostic factor. Mod Pathol 16:1199–1204PubMedCrossRefGoogle Scholar
  8. 8.
    Sano H, Kawahito Y, Wilder RL et al (1995) Expresión of cyclooxigenase-1 and -2 in human colorectal cancer. Cancer Res 55:3789–3789Google Scholar
  9. 9.
    Yoshimatsu K, Nasser K, Golijanin D et al (2001) Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 7:2669–2674PubMedGoogle Scholar
  10. 10.
    Karmali RA, Wustrow T, Thaler HT, Strong EW (1984) Prostaglandins in carcinomas of the head and neck. Cancer Lett 22:333–336PubMedCrossRefGoogle Scholar
  11. 11.
    Jung TK, Berlinger NT, Juhn SK (1985) Prostaglandins in squamous cell of the head and neck: a preliminary study. Laryngoscope 95:307–312PubMedCrossRefGoogle Scholar
  12. 12.
    Tsujii M, Kawano S, Tsuji S et al (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705–716PubMedCrossRefGoogle Scholar
  13. 13.
    Rueda A, Cazorla O, Pérez L et al (2011) Vascular endotelial growth factor and vascular endotelial growth factor receptor-2 tumor expresión in patients with advanced laryngeal cancer alter induction chemotherapy for organ preservation. Head Neck 33:808–816PubMedCrossRefGoogle Scholar
  14. 14.
    Kyzas PA, Stefanou D, Agnantis NJ (2005) COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma. Mod Pathol 18:153–160PubMedCrossRefGoogle Scholar
  15. 15.
    Xu CZ, Dong P, Li XY et al (2009) Expression and clinical significante of hypoxia-inducible factor-1alpha and cyclooxigenase-2 in laryngeal squamous cell carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 44:57–62Google Scholar
  16. 16.
    Fosslien E (2000) Molecular pathology of cyclooxigenase-2 in neoplasia. Ann Clin Lab Sci 30:3–21PubMedGoogle Scholar
  17. 17.
    Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493–501PubMedCrossRefGoogle Scholar
  18. 18.
    Dohadwala M, Luo J, Zhu L et al (2001) Non-small cell lung cancer cyclo-oxigenase 2 dependent invasión is mediated by CD44. j. Biol Chem 276:809–812Google Scholar
  19. 19.
    Davies G et al (2003) Correlation between cyclooxigenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 9:2651–2656PubMedGoogle Scholar
  20. 20.
    Ranelletti FO et al (2001) Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. Int J Cancer 95:343–349PubMedCrossRefGoogle Scholar
  21. 21.
    Sackett MK, Bairati I, Meyer F et al (2008) Prognostic significance of cyclooxygenase-2 overxpression in glottis cancer. Clin Cancer Res 14:67–73PubMedCrossRefGoogle Scholar
  22. 22.
    Cho EI, Kowalski DP, Sasaki CT et al (2004) Tissue microarray analysis reveals prognostic significance of COX-2 expression for local relapse in T1–2N0 larynx cancer treated with primary radiation therapy. Laryngoscope 114:2001–2008PubMedCrossRefGoogle Scholar
  23. 23.
    Danneberg AJ, Altorki NK, Boyle JO et al (2001) Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2:544–551CrossRefGoogle Scholar
  24. 24.
    Soo R, Putti T, Tao Q et al (2005) Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression. Arch Otolaryngol Head Neck Surg 131:147–152PubMedCrossRefGoogle Scholar
  25. 25.
    Qin G, Liang Q, Yu L et al (2010) Expression and significance of COX-2 and S-100 positive dendritic cell in laryngeal carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 24:101–104Google Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2012

Authors and Affiliations

  • Elisabeth Pérez-Ruiz
    • 1
  • O. Cazorla
    • 2
  • M. Redondo
    • 3
  • L. Pérez
    • 4
  • M. Álvarez
    • 4
  • E. Gallego
    • 4
  • J. M. Trigo
    • 5
  • J. A. Medina
    • 6
  • A. Matilla
    • 4
  • A. Rueda
    • 1
  1. 1.Division of Medical Oncology, Oncology departmentHospital Costa del SolMarbella, MalagaSpain
  2. 2.Division of OtolaryngologyAntequera, MálagaSpain
  3. 3.Department of BiochemistryCIBER ESP, Hospital Costa del SolMarbellaSpain
  4. 4.Department of Pathological AnatomyHospital Virgen de la VictoriaMálagaSpain
  5. 5.Division of Medical OncologyHospital Virgen de la VictoriaMálagaSpain
  6. 6.Division of RadiotherapyHospital Virgen de la VictoriaMálagaSpain

Personalised recommendations